It has been reported that the selective 5-HT2A receptor antagonist M100907 suppresses pressure overload-induced cardiac hypertrophy by inhibiting the CaMKII/HDAC4 pathway [42]. This evidence concerns the gene HDAC4 and cardiac hypertrophy.